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Obturator  Nerve  Block  with  Botulinum  Toxin  Type  B  for 
Patient  with Adductor Thigh Muscle Spasm
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Obturator nerve block has been commonly used for pain management to prevent involuntary reflex of the 
adductor thigh muscles. One of several options for this block is chemical neurolysis. Neurolysis is done with 
chemical agents. Chemical agents used in the neurolysis of the obturator nerve have been alcohol, phenol, 
and botulinum toxin. In the current case, a patient with spasticity of the adductor thigh muscle due to cervical 
cord injury had obturator nerve neurolysis done with botulinum toxin type B (BoNT-B). Most of the previous 
stu dies h ave used B oN T -A  w ith  on ly a few  r ep o rts th at have u sed  Bo N T -B . Bo N T -B h as several ad van tages 
and disadvantages over BoNT-A. Thus, we report herein a patient who successfully received obturator nerve 
neurolysis using BoNT-B to treat adductor thigh muscle spasm. (Korean  J  Pain  2011;  24:  164-168)
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    Diseases that are known to cause spasticity of the thigh 
adductor muscle include stroke, spinal cord injury, brain 
injury, and multiple sclerosis, and the major mechanism is 
damage of the upper motor neuron. The purpose of lower 
limb spasticity management is to reduce pain by reducing 
muscular overactivity and advancing the articular range of 
motion and thereby improving the quality of life [1]. The 
treatment of lower limb spasticity is divided into internal 
medical treatment and neurolysis. Antispastic medication 
includes benzodiazepines, dantrolene, tizanidine, and ba-
clofen. However, long-term use of these drugs has been 
reported to cause side effects such as hepatotoxicity, se-
dation, and dizziness [2]. The agents for chemical neu-
rolysis include phenol, alcohol, and botulinum toxin (BoNT). 
Ph en o l an d  a l co h o l ca uses a n erv e b l oc k b y d e n a t uring 
proteins, resulting in neural tissue damage. On the other 
hand, BoNT causes a nerve block by repressing the secre-
tion of acetylcholine at the presynaptic nerve ending [3]. 
BoNT has the advantage of reducing spasticity and achiev-
ing nerve block without any tissue damage by injecting it EJ Choi, et al / Obturator Nerve Block with Botulinum Toxin Type B 165
Fig. 1. Injection of anterior branch of obturator nerve 
visualized along focal hyperechoic interfascial line. An 
anterior branch of obturator nerve is located adductor 
longus muscle (ALM) and adductor brevis muscles (ABM).
directly into a muscle or the part near the nerve. Among 
the seven types of BoNT, Types A (BoNT-A) and Type B 
(BoNT-B) are used clinically. BoNT-A has been used for 
the  reduction  of  spasticity  in  previous  studies  [1,4],  but 
BoNT-B has not. We were able to successful reduce lower 
limb  spasticity  through  obturator  nerve  block  neurolysis 
using BoNT-B in a patient with lower limb spasticity due 
to cervical cord injury. Therefore, we report our case with 
a review of the literature.
CASE  REPORT
    A 36-year old man, 165 cm and 61.1 kg in height and 
weight, experienced cervical cord injury (C3-C4) due to a 
motorbike accident in December 2009 resulting in secon-
dary quadriplegia. The patient did not have any specific 
findings  in  the  medical  history.  The  patient  underwent 
posterior laminectomy and fusion of the C3-5 level be-
cause of the instability of the cervical spine in March 2010. 
The patient was sent to a pain clinic at our hospital in June 
2010 because of severe lower limb spasticity due to secon-
dary quadriplegia. At that time, the spasticity index was 
1/1 at the elbow, 3/3 at the hip joint, 3/3 at the knee, and 
1＋/1＋ at the ankle according to the modified Ashworth 
scale [5]. The lower limb spasticity of the patient was ex-
a cer bated by the su pine position and minima l irritation. 
Treatment for rehabilitation was hard to do because of the 
involuntary flexion. In particular, an operation was needed 
because of a severe coccyx sore but it could not be done 
because the patient was not able to take the prone position 
due to the spasticity. The department of rehabilitation had 
been injecting dantrolene 200 mg and baclofen 50 mg per 
day for five months to reduce spasticity, which was similar 
to the maximum dose of each drug but there was no par-
ticular improvement in the spasticity.
    W e decided to perform chemodenervation of the ob-
turator nerve using BoNT-B (MYOBLOC
TM, Solstice neuro-
sciences, USA) to reduce the lower limb spasticity of the 
patient. A sufficient explanation was provided to the pa-
tient about the operation and its complications and written 
consent was received from him. There were no abnormal 
findings  in  the  preoperative  blood  test,  urinalysis,  and 
electrocardiography (ECG). During the operation, we moni-
tored the blood pressure, ECG, and pulse oxygen satu-
ration. The patient took the supine position, but the in-
voluntary flexion was so severe because of the lower limb 
spasticity that he opened the hip joint as much as possible 
with the help of an assistant and fixed both lower limbs 
while bending the knee joints. The operative region was 
coated with Betadine and coveted with a sterile covering. 
Then, the pubic tubercle and anterior superior iliac spine 
were identified. On the line connecting the two points, the 
locations of the femoral artery and femoral vein were found 
using an ultrasound linear probe (6-13 MHz, MicroMAXX
TM, 
Sonosite, USA). Moving the linear probe medially and dis-
tally, we first checked the pectineus muscle and then the 
adductor longus as well as the adductor brevis. Later, we 
identified the interfascial layer in between the two adduc-
tors and then the anterior branch of the obturator nerve. 
We identified the posterior branch of the obturator nerve 
by moving the linear probe to the inner side since it exists 
at the interfascial layer between the adductor brevis and 
the adductor magnus. Local anesthesia was done with 1% 
lidocaine and a 22-G needle was inserted to the inter-
fascial layer where the anterior branch of the obturator 
nerve is. After checking the hydrodissection by injecting 
1 ml of 2% lidocaine, 5 ml of 2% lidocaine was injected 
slowly (Fig. 1). In the same manner, the needle was in-
serted to the interfascial layer between the adductor brevis 
and the adductor magnus where the posterior branch of 
the obturator nerve is to do a diagnostic block (Fig. 2). The 
nerve block was also done to the anterior and posterior 166 Korean J Pain Vol. 24, No. 3, 2011
Fig. 2. Injection of posterior branch of obturator nerve. 
Needle tip positioned between adductor brevis (ABM) and 
adductor magnus muscles (AMM). 
branches of the obturator nerve on the opposite side one 
by one in the same manner. While the patient was in the 
supine position for 30 minutes, we observed if lower limb 
spasticity  was  reduced  and  if  other  complications  took 
place. After 30 minutes, the spasticity index was reduced 
from 3/3 to 1＋/1＋ without any complications. We decided 
to do the chemodenervation of the obturator nerve using 
BoNT-B and approached it in the same manner through 
the  marked  region  from  the  diagnostic  block.  BoNT-B 
1,250 units to each branch and 2,500 units to each of the 
both obturator nerves were injected. The total dose was 
5,000 units. We verified that there were no complications 
by catamnesis for 30 minutes after we finished the pro-
cedure. The follow-up observation of three months after 
the procedure showed that the spasticity of the hip joint 
was maintained at 1＋/1＋, and the involuntary reflex was 
reduced greatly.
DISCUSSION 
    As in this case, lower limb spasticity due to quad-
r i p l e g i a  i n c r e a s e s  m u s c l e  t o n e  a n d  s t r e t c h  r e f l e x  a n d  
thereby, results in problems such as causing discomfort in 
patients,  interfering  with  rehabilitation  treatment,  and 
lowering perineal hygiene [1]. Thus, obturator nerve blocks 
are done to relax the hip adductor muscles involved in lower 
limb spasticity. Generally, a diagnostic nerve block is fol-
lowed by chemodenervation using alcohol and phenol in or-
der  to  extend  the  period  of  the  obturator  nerve  block. 
BoNT is used with two methods: direct injection of BoNT 
into the adductor muscles causing lower limb spasticity and 
obturator nerve block. There has been a report that the 
reduction of spasticity was achieved by directly injecting 
BoNT-A into the adductor muscles, but there has been no 
report  on  obturator  nerve  block  using  BoNT  to  our 
knowledge.
    BoNT has been used to treat various diseases since 
Scott [6] treated a patient with strabismus by injecting it 
to the affected muscles. Since BoNT acts through the in-
hibition of acetylcholine secretion, it can affect all regions 
where  acetylcholine  is  secreted  including  the  neuromu-
s c u l a r  j u n c t i o n ,  p r e g a n g l i o n i c  n e u r o n ,  a n d  p a r a s y m -
pathetic post ganglionic neuron. For instance, BoNT can 
be used to treat cervical dystonia and hemifacial spasm, 
which are caused by hyperactivity of the muscles, and to 
treat hyperhidrosis, which is caused by excessive activation 
of sweat glands innervated by the sympathetic nerve [7,8]. 
Recently, BoNT has been used to treat various diseases 
including complex regional pain syndrome and overactive 
bladder and to perform sympathetic nerve blocks [9,10]. 
BoNT has been classified into seven types: types A, B, C, 
D, E, F, and G depending on the type of antigen. Among 
t h e m ,  o n l y  t y p e s  A  a n d  B  a r e  u s e d  c l i n i c a l l y  [ 3 ] .  B o t h 
BoNT-A and BoNT-B seem to both inhibit acetylcholine 
secretion, but their mechanisms for inhibition and target 
proteins are different. BoNT-A binds to SNAP-25 (synap-
tosomal-associated protein 25), which is one of the sub-
units of SNARE (soluble N-ethylmaleimide-sensitive-factor 
attachment  protein  receptor)  that  causes  fusion  of  the 
presynaptic  membrane  and  synaptic  vesicles  and  thus, 
cleaves  the  synaptic  vesicles  so  that  they  cannot  fuse. 
However, BoNT-B inhibits acetylcholine secretion by cleav-
ing the synaptobrevin involved in the exocytosis of ace-
tylcholine [11]. The different target proteins affects the du-
ration of action of BoNT-A and BoNT-B. According to a 
study that compared the duration of action of BoNT-A and 
BoNT-B in the treatment of cervical dystonia, the duration 
of action of BoNT-B was 12.1 weeks and that of BoNT-A 
14 weeks (P = 0.033), indicating that BoNT-B had a short-
er duration of action than that of BoNT-A. Another draw-
back of BoNT-B is that the incidence of dry mouth and 
dysphagia are not rare and the incidence rate is higher 
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that the use of BoNT-B was ne v er stopped because of 
complications since most of them were mild. BoNT-B has 
several advantages over BoNT-A. First, BoNT-B is effec-
tive for managing patients with Type A-resistance. BoNT 
is often injected repeatedly. One report has stated that 
5-10% of patients showed resistance when BoNT-A was 
repeatedly injected o v er a short in terv al of tw o mon ths 
[13]. It is also known that treatment with BoNT-B is effec-
tive without showing any particular resistant among such 
patients [14]. Second, BoNT-B is more stable than BoNT-A. 
BoNT-A is produced in a powder formulation to avoid lyo-
philization whereas BoNT-B is produced in a liquid formu-
lation. BoNT-B is stored at room temperature or in a re-
frigerator (2-25
oC). In addition, BoNT-B is stable in the 
sense that the potency does not decrease over time even 
after  initially  opening  the  container.  However,  BoNT-A 
should be kept in a freezer (-5
oC) or refrigerator and must 
be used within four hours after diluting it with 0.9% saline 
solution under refrigeration [15]. In other words, the liquid 
form of BoNT-B can be used for injection until supplies 
r u n  o u t ,  w h i l e  t h e  r e c o n s t i t u t e d  l y o p h i l i z e d  p o w d e r  o f  
BoNT-A in 0.9% saline solution has to be used within four 
hours after dilution. Thus, injection treatment should be 
carefully planned when using BoNT-A. 
    The greatest advantage of chemodenervation with 
BoNT compared with alcohol and phenol is that the damage 
to the surrounding tissues can be minimized. Alcohol and 
phenol cause nerve blocks by denaturing proteins and in-
advertent dysesthesia or chemical neuritis may accompany 
the treatment [16]. These may be due to abnormal re-
actions following permanent protein denaturation or com-
plications caused by the diffusion of the chemical agents 
to the surrounding tissues. However, BoNT does not have 
s u c h  c o m p l i c a t i o n s  b e c a u s e  i t  j u s t  i n h i b i t s  a c e t y l c h o l i n e 
secretion and does not cause tissue denaturation. In this 
case report, BoNT was injected to the surrounding regions 
of the obturator nerve to achieve reduced spasticity of the 
thigh adductors, which is different from previous case re-
ports where BoNT was directly injected into the muscles. 
One animal study on the mechanism of BoNT reported that 
the injected BoNT permeates to the nerve sheath and in-
hibits acetylcholine secretion at the neuromuscular junc-
tions [17]. This means that BoNT injection into a region 
around a nerve can also have the effect of reducing spas-
ticity, which is the same as direct BoNT injection into the 
muscles. BoNT-B may be more useful for intramuscular 
injection and nerve block than BoNT-A since BoNT-B dif-
fuses to the surrounding tissues to a lesser degree than 
that of BoNT-A as reported by [18]. However, this property 
may be a drawback of BoNT when compared with with al-
cohol or phenol. For example, one study showed that it 
took about 91 days to recover the function of the neuro-
muscular junction after the injection of BoNT was [19]. This 
period of time is almost the same as the duration of action 
of BoNT, which is 2-3 months [3]. Since the duration of 
action is shorter than the mean duration of action of alco-
hol and phenol, the nerve block has to be done repeatedly, 
which is expensive. However, this may be compensated by 
BoNT-A since it was reported to be superior in terms of 
cost-effectiveness  in  cases  where  an  anti-spastic  drug 
was first injected into patients with lower limb spasticity 
compared  to  cases  where  a  reduction  in  spasticity  was 
achieved with BoNT-A [20]. With respect to the BoNT-B 
dosage, one study reported that no significant complica-
tions were found when an initial dosage of 2,500-10,000 
units was given to patients with cervical dystonia [18]. In 
our case for both obturator nerve blocks, we used 2,500 
units each for the right and left sides. We thought it ap-
propriate not to increase the initial dosage greatly unless 
the  patient  had  undergone  BoNT  treatment  in  advance. 
BoNT-B and BoNT-A both have pros and cons. It is im-
portant to select the more appropriate one depending on 
the case. Further studies are need so that BoNT-B may 
be used more widely in chemodenervation.
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